EE05051B1 - Fumaarhappe derivaadid kasutamiseks mitokondriaalsete haiguste ravis - Google Patents

Fumaarhappe derivaadid kasutamiseks mitokondriaalsete haiguste ravis

Info

Publication number
EE05051B1
EE05051B1 EEP200200333A EEP200200333A EE05051B1 EE 05051 B1 EE05051 B1 EE 05051B1 EE P200200333 A EEP200200333 A EE P200200333A EE P200200333 A EEP200200333 A EE P200200333A EE 05051 B1 EE05051 B1 EE 05051B1
Authority
EE
Estonia
Prior art keywords
fumaric acid
treatment
mitochondrial diseases
acid derivatives
sdh
Prior art date
Application number
EEP200200333A
Other languages
English (en)
Estonian (et)
Inventor
Kumar Joshi Rajendra
Strebel Hans-Peter
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of EE200200333A publication Critical patent/EE200200333A/xx
Publication of EE05051B1 publication Critical patent/EE05051B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
EEP200200333A 2000-01-10 2000-12-11 Fumaarhappe derivaadid kasutamiseks mitokondriaalsete haiguste ravis EE05051B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10000577A DE10000577A1 (de) 2000-01-10 2000-01-10 Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
PCT/EP2000/012504 WO2001051047A1 (de) 2000-01-10 2000-12-11 Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten

Publications (2)

Publication Number Publication Date
EE200200333A EE200200333A (et) 2003-08-15
EE05051B1 true EE05051B1 (et) 2008-08-15

Family

ID=7627026

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200333A EE05051B1 (et) 2000-01-10 2000-12-11 Fumaarhappe derivaadid kasutamiseks mitokondriaalsete haiguste ravis

Country Status (28)

Country Link
US (1) US6858750B2 (da)
EP (1) EP1248606B1 (da)
JP (1) JP2003529556A (da)
CN (1) CN1433303A (da)
AT (1) ATE329590T1 (da)
AU (1) AU772409B2 (da)
BG (1) BG65468B1 (da)
BR (1) BR0016935A (da)
CA (1) CA2390886C (da)
CY (1) CY1105462T1 (da)
CZ (1) CZ303680B6 (da)
DE (2) DE10000577A1 (da)
DK (1) DK1248606T3 (da)
EE (1) EE05051B1 (da)
ES (1) ES2265367T3 (da)
HU (1) HU229138B1 (da)
IL (2) IL150516A0 (da)
MX (1) MXPA02006695A (da)
NO (1) NO326875B1 (da)
NZ (1) NZ518781A (da)
PL (1) PL223342B1 (da)
PT (1) PT1248606E (da)
RS (1) RS50185B (da)
RU (1) RU2218918C1 (da)
SI (1) SI1248606T1 (da)
SK (1) SK286719B6 (da)
WO (1) WO2001051047A1 (da)
ZA (1) ZA200205481B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
CZ304198B6 (cs) 2001-01-12 2013-12-27 Fumapharm Ag Amidy kyseliny fumarové
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
US7224426B2 (en) * 2002-07-31 2007-05-29 Dai Nippon Printing Co., Ltd. Optical element
CA2526586C (en) 2003-09-09 2010-03-16 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
HUE031950T2 (en) * 2004-10-08 2017-08-28 Forward Pharma As Controlled release pharmaceutical compositions containing fumaric acid ester
DE602006011910D1 (de) * 2005-07-07 2010-03-11 Aditech Pharma Ag Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
WO2007006307A2 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
AU2007328210B2 (en) * 2006-12-06 2012-11-22 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
EP2137537B8 (en) 2007-02-08 2016-06-01 Biogen MA Inc. Compositions and Uses for Treating Multiple Sclerosis
RS55215B1 (sr) * 2007-02-08 2017-02-28 Biogen Ma Inc Neuroprotekcija kod demijelinizacionih bolesti
AU2009282888C1 (en) * 2008-08-19 2014-01-23 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
PT2564839T (pt) 2009-01-09 2016-07-14 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
WO2010079221A1 (en) * 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
WO2010107488A1 (en) 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
WO2011022491A1 (en) 2009-08-19 2011-02-24 Cornell University Cysteine for physiological injection
US20140142095A1 (en) * 2011-04-28 2014-05-22 Serket Pharma, Llc Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
AU2012267524A1 (en) 2011-06-08 2013-12-12 Biogen Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
PE20150092A1 (es) * 2012-02-07 2015-02-06 Biogen Idec Inc Composiciones farmaceuticas que contienen fumarato de dimetilo
EP2812319A1 (en) 2012-02-07 2014-12-17 XenoPort, Inc. Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
CA2882730C (en) 2012-08-22 2019-12-31 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CN105142628A (zh) 2012-12-21 2015-12-09 比奥根玛公司 氘取代的富马酸盐衍生物
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
DK2970101T3 (da) 2013-03-14 2018-08-20 Alkermes Pharma Ireland Ltd Pro-drugs af fumarater og deres anvendelse i behandling af forskellige sygdomme
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
PL3253377T3 (pl) 2015-02-08 2021-09-27 Alkermes Pharma Ireland Limited Kompozycje proleku fumaranu monometylu
DK3273951T3 (da) 2015-03-27 2020-11-02 Symbionyx Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af psoriasis
CA2987895A1 (en) 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
RU2674286C1 (ru) * 2018-03-20 2018-12-07 Исмагилов Искандар Халиуллович Средство для лечения заболевания, обусловленного нарушением окислительного стресса
RU2742745C1 (ru) * 2019-09-24 2021-02-10 Акционерное общество "Исследовательский Институт Химического Разнообразия" Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JPS61194020A (ja) * 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
IT1251166B (it) * 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
AU1945495A (en) * 1994-03-16 1995-10-03 Novo Nordisk A/S Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
WO2002002190A2 (en) * 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes

Also Published As

Publication number Publication date
CA2390886C (en) 2008-08-19
SK286719B6 (sk) 2009-04-06
CZ20021522A3 (cs) 2002-10-16
EE200200333A (et) 2003-08-15
ES2265367T3 (es) 2007-02-16
YU51402A (sh) 2006-01-16
IL150516A0 (en) 2003-02-12
SK6522002A3 (en) 2002-11-06
US20030013761A1 (en) 2003-01-16
NO20022175L (no) 2002-05-07
SI1248606T1 (sl) 2006-10-31
CZ303680B6 (cs) 2013-02-27
DK1248606T3 (da) 2006-08-21
AU772409B2 (en) 2004-04-29
JP2003529556A (ja) 2003-10-07
IL150516A (en) 2009-02-11
DE10000577A1 (de) 2001-07-26
PT1248606E (pt) 2006-08-31
ZA200205481B (en) 2004-01-28
PL356714A1 (en) 2004-06-28
CY1105462T1 (el) 2010-04-28
BR0016935A (pt) 2003-04-01
EP1248606A1 (de) 2002-10-16
NO20022175D0 (no) 2002-05-07
WO2001051047A8 (de) 2001-08-16
DE50013000D1 (de) 2006-07-27
PL223342B1 (pl) 2016-10-31
RS50185B (sr) 2009-05-06
NZ518781A (en) 2004-04-30
CN1433303A (zh) 2003-07-30
NO326875B1 (no) 2009-03-09
BG106685A (en) 2003-01-31
HUP0204182A3 (en) 2003-05-28
AU3156601A (en) 2001-07-24
WO2001051047A1 (de) 2001-07-19
CA2390886A1 (en) 2001-07-19
RU2218918C1 (ru) 2003-12-20
ATE329590T1 (de) 2006-07-15
HUP0204182A2 (hu) 2003-04-28
EP1248606B1 (de) 2006-06-14
HU229138B1 (en) 2013-08-28
US6858750B2 (en) 2005-02-22
BG65468B1 (bg) 2008-09-30
MXPA02006695A (es) 2002-10-23

Similar Documents

Publication Publication Date Title
EE200200333A (et) Fumaarhappe derivaatide kasutamine mitokondriaalsete haiguste raviks
UA74346C2 (uk) Похідні амінодикарбонових кислот, їх застосування та лікарський засіб
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
NZ514234A (en) N-cyanomethylamides as protease inhibitors
TR200200648T2 (tr) Farmasötik özelliklere sahip yeni dikarboksilik asit türevleri.
TR199801642T2 (xx) Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
CY1107600T1 (el) Κρεμα για τη θepαπεια δερματος τραυματισμενου απο τον ηλιο
WO2003037323A3 (en) Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
MXPA02006249A (es) Nuevos derivados de azabiciclooctano, utiles en el tratamiento de arritmias cardiacas.
ATE311866T1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur
RS50129B (sr) Optički aktivan derivat piridil-4h-1,2,4-oksadiazina i njegova upotreba u proizvodnji lekova za tretiranje vaskularnih bolesti
DE60122917D1 (de) Fermentative herstellung von d-p-hydroxyphenylglycin und d-phenylglycin
CY1106168T1 (el) Συνθεση για την προληψη και/ή θepαπεια αγγειακων ασθενειων που συνισταται απο προπιονυλ l-καρνιτινη και συνενζυμο q10
IL163344A (en) 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid derivative compounds, process for their synthesis and compositions comprising the compounds as the active ingredient
MY122830A (en) Process for the preparation of (alpha)-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
ATE330597T1 (de) Verwendung von fibrate zur herstellung eines arzneimittel zur behandlung von kongestiven herzversagens
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
DE59801192D1 (de) Delta-aminolävulinsäure enthaltendes arzneimittel
NO20044555L (no) Kombinasjonsprodukt omfattende en antikoagulant og anti-arrytmiske oksabispidener
ATE129244T1 (de) 4-((thiophen-2-carbonyl)oxy&gt;pyrrolidin-2- carbonsäure, deren herstellung und deren verwendung als entzündungshemmendes und wundheilendes mittel.
HUP0301647A2 (hu) Fibrátok alkalmazása kongesztív szívelégtelenség kezelésére használható gyógyszerkészítmény előállítására
UA41037A (uk) Препарат для лікування захворювань порожнини роту

Legal Events

Date Code Title Description
HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner
HD1A Correction of address
MM4A Lapsed by not paying the annual fees

Effective date: 20161211